Discover
AZTR
Azitra, Inc.
0.14
1 x 0.14
3 x 0.14
bid
ask
-
0.01
7.05%
99 @ 04:00 PM
0.14 +0.00 (0.22%)
| Ytd | -48.75% | |
| 1y | -91.19% |
0.13
day range
0.14
0.10
52 week range
1.60
| Open | 0.14 | Prev Close | 0.15 | Low | 0.13 | High | 0.14 | Mkt Cap | 1.46M |
| Vol | 454.41K | Avg Vol | 11.64M | EPS | -3.27 | P/E | -0.04 | Forward P/E | -0.78 |
| Beta | -1.21 | Short Ratio | 1.34 | Inst. Own | 1.82% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | N/A | 50-d Avg | 0.19 | 200-d Avg | 0.29 | 1yr Est | 3.50 |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|
Profile
Azitra, Inc., an early-stage biopharmaceutical company, develops therapies for precision dermatology using engineered proteins and live biotherapeutic products to treat skin diseases. It develops ATR-12, a genetically modified strain of S. epidermidis, which is in Phase Ib clinical trial for treating Netherton syndrome, a skin disease. The company also develops ATR-04, a genetically modified strain of S. epidermidis for treating the papulopustular rash experienced by cancer patients undergoing epidermal growth factor receptor inhibitor; and ATR-01, an engineered recombinant human filaggrin protein for treating ichthyosis vulgaris, a skin disease. It has a collaboration with Bayer. The company was incorporated in 2014 and is based in Branford, Connecticut.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2023-06-20 | BAYER HEALTHCARE L.L.C. | Beneficial Owner of more than 10% of a Class of Security | 0.00 | Conversion of Exercise of derivative security |
| 2023-06-20 | FLETCHER AARON G.L. | Beneficial Owner of more than 10% of a Class of Security | 0.00 | Purchase |
| 2023-06-20 | KREIS LESLIE W JR | Beneficial Owner of more than 10% of a Class of Security | 0.00 | Purchase |
| 2023-06-20 | MCCLARY ANDREW | Director | 0.00 | Conversion of Exercise of derivative security |
| 2024-02-12 | SALVA FRANCISCO D | Chief Executive Officer | 338.30K | Purchase |
| 2024-03-27 | STASKEY NORM | Chief Financial Officer | 51.10K | Purchase |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Warberg Asset Management LLC | 48.80K | 19.91K | 0.64% |
| 2024-09-29 | Two Sigma Securities, LLC | 34.16K | 13.94K | 0.45% |
| 2024-09-29 | Geode Capital Management, LLC | 27.10K | 11.06K | 0.36% |
| 2024-09-29 | Virtu Financial LLC | 21.31K | 8.70K | 0.28% |
| 2024-09-29 | National Bank of Canada/FI | 5.00K | 2.04K | 0.07% |
| 2024-09-29 | Tower Research Capital LLC (TRC) | 799.00 | 325.00 | 0.01% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-10-30 | Fidelity Extended Market Index Fund | 26.60K | 10.85K | 0.35% |
| 2024-10-30 | Fidelity Series Total Market Index Fund | 7.56K | 3.08K | 0.10% |
Split
| Split | Date |
|---|---|
| 1 : 6 | 2025-08-21 |
| 1 : 30 | 2024-07-01 |